FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3203604241> ?p ?o ?g. }

• W3203604241 endingPage "e777" @default.
• W3203604241 startingPage "e767" @default.
• W3203604241 abstract "Background Owing to increasing remission rates, the management of patients with rheumatoid arthritis in sustained remission is of growing interest. The Rheumatoid Arthritis in Ongoing Remission (RETRO) study investigated tapering and withdrawal of disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis in stable remission to test whether remission could be retained without the need to take DMARD therapy despite an absence of symptoms. Methods RETRO was an investigator-initiated, multicentre, prospective, randomised, controlled, open-label, parallel-group phase 3 trial in patients aged at least 18 years with rheumatoid arthritis for at least 12 months before randomisation who were in sustained Disease Activity Score using 28 joints with erythrocyte sedimentation rate (ESR) remission (score <2·6 units). Eligible patients were recruited consecutively from 14 German hospitals or rheumatology practices and randomly assigned (1:1:1) without stratification and regardless of baseline treatment, using a sequence that was computer-generated by the study statistician, to continue 100% dose DMARD (continue group), taper to 50% dose DMARD (taper group), or 50% dose DMARD for 6 months before stopping DMARDs (stop group). Neither patients nor investigators were masked to the treatment assignment. Patients were assessed every 3 months and screened for disease activity and relapse. The primary endpoint was the proportion of patients in sustained DAS28-ESR remission without relapse at 12 months, analysed using a log-rank test of trend and Cox regression. Analysis by a trained statistician of the primary outcome and safety was done in a modified intention-to-treat population that included participants with non-missing baseline data. This study is completed and closed to new participants and is registered with ClinicalTrials.gov (NCT02779114). Findings Between May 26, 2010, and May 29, 2018, 303 patients were enrolled and allocated to continue (n=100), taper (n=102), or stop DMARDs (n=101). 282 (93%) of 303 patients were analysed (93 [93%] of 100 for continue, 93 [91%] of 102 for taper, and 96 [95%] of 101 for stop). Remission was maintained at 12 months by 81·2% (95% CI 73·3–90·0) in the continue group, 58·6% (49·2–70·0) in the taper group, and 43·3% (34·6–55·5) in the stop group (p=0·0005 with log-rank test for trend). Hazard ratios for relapse were 3·02 (1·69–5·40; p=0.0003) for the taper group and 4·34 (2·48–7·60; p<0.0001)) for the stop group, in comparison with the continue group. The majority of patients who relapsed regained remission after reintroduction of 100% dose DMARDs. Serious adverse events occurred in ten of 93 (11%) patients in the continue group, seven of 93 (8%) patients in taper group, and 13 of 96 (14%) patients in the stop group. None were considered to be related to the intervention. The most frequent type of serious adverse event was injuries or procedural complications (n=9). Interpretation Reducing antirheumatic drugs in patients with rheumatoid arthritis in stable remission is feasible, with maintenance of remission occurring in about half of the patients. Because relapse rates were significantly higher in patients who tapered or stopped antirheumatic drugs than in patients who continued with a 100% dose, such approaches will require tight monitoring of disease activity. However, remission was regained after reintroduction of antirheumatic treatments in most of those who relapsed in this study. These results might help to prevent overtreatment in a substantial number of patients with rheumatoid arthritis. Funding None." @default.
• W3203604241 created "2021-10-11" @default.
• W3203604241 creator A5002520863 @default.
• W3203604241 creator A5004105963 @default.
• W3203604241 creator A5009444018 @default.
• W3203604241 creator A5012973190 @default.
• W3203604241 creator A5013085430 @default.
• W3203604241 creator A5013492221 @default.
• W3203604241 creator A5016601495 @default.
• W3203604241 creator A5022588052 @default.
• W3203604241 creator A5033544980 @default.
• W3203604241 creator A5033815543 @default.
• W3203604241 creator A5037760876 @default.
• W3203604241 creator A5038489074 @default.
• W3203604241 creator A5040409271 @default.
• W3203604241 creator A5042208174 @default.
• W3203604241 creator A5045378260 @default.
• W3203604241 creator A5045623356 @default.
• W3203604241 creator A5052829977 @default.
• W3203604241 creator A5052909163 @default.
• W3203604241 creator A5053190244 @default.
• W3203604241 creator A5056323490 @default.
• W3203604241 creator A5059789259 @default.
• W3203604241 creator A5063235068 @default.
• W3203604241 creator A5066439668 @default.
• W3203604241 creator A5070887882 @default.
• W3203604241 creator A5074627741 @default.
• W3203604241 creator A5075261558 @default.
• W3203604241 creator A5079285531 @default.
• W3203604241 creator A5079831828 @default.
• W3203604241 date "2021-11-01" @default.
• W3203604241 modified "2023-10-18" @default.
• W3203604241 title "Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial" @default.
• W3203604241 cites W2011909999 @default.
• W3203604241 cites W2023621352 @default.
• W3203604241 cites W2025591723 @default.
• W3203604241 cites W2028646119 @default.
• W3203604241 cites W2068338283 @default.
• W3203604241 cites W2077672930 @default.
• W3203604241 cites W2107756455 @default.
• W3203604241 cites W2110177517 @default.
• W3203604241 cites W2110826367 @default.
• W3203604241 cites W2112953069 @default.
• W3203604241 cites W2114909821 @default.
• W3203604241 cites W2143212689 @default.
• W3203604241 cites W2152348310 @default.
• W3203604241 cites W2164312146 @default.
• W3203604241 cites W2168751860 @default.
• W3203604241 cites W2204687884 @default.
• W3203604241 cites W2220905733 @default.
• W3203604241 cites W2254589607 @default.
• W3203604241 cites W2279367068 @default.
• W3203604241 cites W2805119855 @default.
• W3203604241 cites W2930984369 @default.
• W3203604241 cites W2943183071 @default.
• W3203604241 cites W2954249951 @default.
• W3203604241 cites W2980610050 @default.
• W3203604241 cites W2995772470 @default.
• W3203604241 cites W3029915612 @default.
• W3203604241 cites W3104310290 @default.
• W3203604241 cites W3111345147 @default.
• W3203604241 cites W4231972505 @default.
• W3203604241 cites W4249063051 @default.
• W3203604241 doi "https://doi.org/10.1016/s2665-9913(21)00220-4" @default.
• W3203604241 hasPublicationYear "2021" @default.
• W3203604241 type Work @default.
• W3203604241 sameAs 3203604241 @default.
• W3203604241 citedByCount "11" @default.
• W3203604241 countsByYear W32036042412021 @default.
• W3203604241 countsByYear W32036042412022 @default.
• W3203604241 countsByYear W32036042412023 @default.
• W3203604241 crossrefType "journal-article" @default.
• W3203604241 hasAuthorship W3203604241A5002520863 @default.
• W3203604241 hasAuthorship W3203604241A5004105963 @default.
• W3203604241 hasAuthorship W3203604241A5009444018 @default.
• W3203604241 hasAuthorship W3203604241A5012973190 @default.
• W3203604241 hasAuthorship W3203604241A5013085430 @default.
• W3203604241 hasAuthorship W3203604241A5013492221 @default.
• W3203604241 hasAuthorship W3203604241A5016601495 @default.
• W3203604241 hasAuthorship W3203604241A5022588052 @default.
• W3203604241 hasAuthorship W3203604241A5033544980 @default.
• W3203604241 hasAuthorship W3203604241A5033815543 @default.
• W3203604241 hasAuthorship W3203604241A5037760876 @default.
• W3203604241 hasAuthorship W3203604241A5038489074 @default.
• W3203604241 hasAuthorship W3203604241A5040409271 @default.
• W3203604241 hasAuthorship W3203604241A5042208174 @default.
• W3203604241 hasAuthorship W3203604241A5045378260 @default.
• W3203604241 hasAuthorship W3203604241A5045623356 @default.
• W3203604241 hasAuthorship W3203604241A5052829977 @default.
• W3203604241 hasAuthorship W3203604241A5052909163 @default.
• W3203604241 hasAuthorship W3203604241A5053190244 @default.
• W3203604241 hasAuthorship W3203604241A5056323490 @default.
• W3203604241 hasAuthorship W3203604241A5059789259 @default.
• W3203604241 hasAuthorship W3203604241A5063235068 @default.
• W3203604241 hasAuthorship W3203604241A5066439668 @default.
• W3203604241 hasAuthorship W3203604241A5070887882 @default.
• W3203604241 hasAuthorship W3203604241A5074627741 @default.
• W3203604241 hasAuthorship W3203604241A5075261558 @default.

• next